We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

51 hedge funds and large institutions have $61.1M invested in Arbutus Biopharma in 2016 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

4% more funds holding

Funds holding: 49 → 51 (+2)

16% less call options, than puts

Call options by funds: $470K | Put options by funds: $560K

16% less capital invested

Capital invested by funds: $73.1M → $61.1M (-$12M)

18% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 17

Holders
51
Holders Change
+2
Holders Change %
+4.08%
% of All Funds
1.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
14
Reduced
17
Closed
6
Calls
$470K
Puts
$560K
Net Calls
-$90K
Net Calls Change
-$239K

Top Buyers

1
AC
Armistice Capital
New York
+$1.73M
2
IGIM
I.G. Investment Management
Manitoba, Canada
+$1.06M
3
Deutsche Bank
Deutsche Bank
Germany
+$423K
4
Morgan Stanley
Morgan Stanley
New York
+$251K
5
KPF
K2 Principal Fund
Ontario, Canada
+$143K

Top Sellers

1
Millennium Management
Millennium Management
New York
-$896K
2
Renaissance Technologies
Renaissance Technologies
New York
-$840K
3
DCM
Dialectic Capital Management
Connecticut
-$740K
4
SFM
Sphera Funds Management
Israel
-$654K
5
BG
Bellevue Group
Switzerland
-$516K
Name Holding Trade Value Shares
Change 		Change in
Stake
Primecap Management
1
Primecap Management
California
$13.4M – – –
AWG
2
Alpha Wave Global
New York
$9.11M – – –
HM
3
HealthCor Management
New York
$7.86M +$123K +29,000 +1%
D.E. Shaw & Co
4
D.E. Shaw & Co
New York
$6.06M +$128K +30,326 +2%
SM
5
Sabby Management
Florida
$4.09M -$90.2K -21,307 -2%
Bank of Montreal
6
Bank of Montreal
Ontario, Canada
$2.82M +$65.4K +15,450 +2%
Axa
7
Axa
France
$2.76M +$46.8K +11,062 +1%
Goldman Sachs
8
Goldman Sachs
New York
$2.37M -$289K -68,185 -9%
Millennium Management
9
Millennium Management
New York
$2.04M -$896K -211,664 -27%
SCM
10
Suffolk Capital Management
New York
$1.54M +$131K +31,023 +8%
AC
11
Armistice Capital
New York
$1.42M +$1.73M +408,000 New
SFM
12
Sphera Funds Management
Israel
$1.04M -$654K -154,500 -34%
IGIM
13
I.G. Investment Management
Manitoba, Canada
$870K +$1.06M +250,000 New
B
14
Bailard
California
$748K – – –
Deutsche Bank
15
Deutsche Bank
Germany
$650K +$423K +99,920 +115%
BBA
16
Baker Bros. Advisors
New York
$628K – – –
CS
17
Credit Suisse
Switzerland
$613K +$508 +120 +0.1%
Morgan Stanley
18
Morgan Stanley
New York
$347K +$251K +59,244 +146%
MIG
19
Mariner Investment Group
New York
$313K – – –
Renaissance Technologies
20
Renaissance Technologies
New York
$272K -$840K -198,585 -72%
DCM
21
DAFNA Capital Management
California
$261K -$170K -40,230 -35%
Ameriprise
22
Ameriprise
Minnesota
$232K -$3.36K -794 -1%
Vanguard Group
23
Vanguard Group
Pennsylvania
$230K -$33.8K -7,991 -11%
KPF
24
K2 Principal Fund
Ontario, Canada
$221K +$143K +33,796 +114%
Mackenzie Financial
25
Mackenzie Financial
Ontario, Canada
$139K – – –
1
2 3

ABUS Hedge Fund Activity: Q2 2016 in Review

51 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q2 2016, worth a combined $61.1M — down 16% from $73.1M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new ABUS positions and 6 closed out — a net gain of 2 holders — while 14 added to existing stakes and 17 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $1.73M. The largest seller was Millennium Management, cutting an estimated $896K.

  • 51 institutional investors held Arbutus Biopharma (ABUS) as of Q2 2016, up from 49 in Q1 2016.
  • Funds reported $61.1M of Arbutus Biopharma stock for Q2 2016, down 16% quarter-over-quarter.
  • 8 funds opened new Arbutus Biopharma positions in Q2 2016 and 6 closed out, a net change of +2 holders.
  • The largest Arbutus Biopharma buyer in Q2 2016 was Armistice Capital, an estimated $1.73M added.
  • The largest Arbutus Biopharma seller in Q2 2016 was Millennium Management, an estimated $896K sold.

Based on aggregated 13F filings for Q2 2016.